engleski

Safe anti-ulcer peptide, (PL-14736, Pliva) in trial for inflammatory bowel disease, stable gastric pentadecapeptide BPC 157 can cure rats with short bowel syndrome complicated with ulcerative colitis

Aim. Stable gastric pentadecapeptide BPC 157 recovered short bowel sydrome in rats after massive small bowel resection, improved intestinal adaptation, villus height, crypt depth, and muscle thickness (and inner (circular) and/or outer (longitudinal) muscular layer)), induced weight gain in weight of normal healthy rats (Dig Dis Sci, 2008 in press). BPC 157 is a safe anti-ulcer peptide (PL-14736, Pliva) in trial for IBD, and wound therapy, no toxicology reported (Gastroenterology, 2005) that healed intestinal anastomosis and fistulas (Dig Dis Sci, 2008, J Pharm Sci, 2008). BPC 157 also prevented and reversed ulcerative colitis induced by cysteamine enema (J Physiol, 1999). However, BPC 157 was not tested after small bowel massive resection in rats with ulcerative colitis. Materials and methods. Small bowel resection. Throughtout a 4 week period we tested rats with escalating bowel syndrome and progressive weight loss that had only 20% of small bowel (Dig Dis Sci, 2008, in press). Ulcerative colitis. Cysteamine enema 400 mg/kg i.r., 1ml/rat. Ulcerative colitis+small bowel resection. Enema was applied at 10 min before surgery. BPC 157 medication. BPC 157 (10 µg, 10ng/kg i.p. or in drinking water) first application 30 min following surgery, last 24 h before sacrifice (7, 14, 21, 28 days). Results. Small bowel resection. The rats had an escalating bowel syndrome and progressive weight loss despite the fourfold muscle thickness increase and twofold villus height and crypt depth increase during the first week. BPC 157 groups recovery showed improved intestinal adaptation, villus height, crypt depth, and muscle thickness (and inner (circular) and/or outer (longitudinal) muscular layer)) additionally increased. The rats immediately gained weight, ultimately to the weight of normal healthy rats. Ulcerative colitis. Controls exhibited pertinent ulceration, initial weight loss, and then decreased weight gain. BPC 157 rats immediately gained weight, ultimately to the weight of normal healthy rats, and had consistently less ulcerations. Ulcerative colitis+small bowel resection. Ulcerative colitis significantly aggravated all these parameters. BPC 157 retained the same beneficial effects, decreased ulcerative colitis, improved intestinal adaptation, villus height, crypt depth, and muscle thickness (and inner (circular) and/or outer (longitudinal) muscular layer)) additionally increased, early weight gain, ultimately to the weight of normal healthy rats. Conclusion. In addition to the recovery of the rats with short bowel syndrome or ulcerative colitis, BPC 157 can cure rats with short bowel syndrome complicated with ulcerative colitis. Aim. Stable gastric pentadecapeptide BPC 157 recovered short bowel sydrome in rats after massive small bowel resection, improved intestinal adaptation, villus height, crypt depth, and muscle thickness (and inner (circular) and/or outer (longitudinal) muscular layer)), induced weight gain in weight of normal healthy rats (Dig Dis Sci, 2008 in press). BPC 157 is a safe anti-ulcer peptide (PL-14736, Pliva) in trial for IBD, and wound therapy, no toxicology reported (Gastroenterology, 2005) that healed intestinal anastomosis and fistulas (Dig Dis Sci, 2008, J Pharm Sci, 2008). BPC 157 also prevented and reversed ulcerative colitis induced by cysteamine enema (J Physiol, 1999). However, BPC 157 was not tested after small bowel massive resection in rats with ulcerative colitis. Materials and methods. Small bowel resection. Throughtout a 4 week period we tested rats with escalating bowel syndrome and progressive weight loss that had only 20% of small bowel (Dig Dis Sci, 2008, in press). Ulcerative colitis. Cysteamine enema 400 mg/kg i.r., 1ml/rat. Ulcerative colitis+small bowel resection. Enema was applied at 10 min before surgery. BPC 157 medication. BPC 157 (10 µg, 10ng/kg i.p. or in drinking water) first application 30 min following surgery, last 24 h before sacrifice (7, 14, 21, 28 days). Results. Small bowel resection. The rats had an escalating bowel syndrome and progressive weight loss despite the fourfold muscle thickness increase and twofold villus height and crypt depth increase during the first week. BPC 157 groups recovery showed improved intestinal adaptation, villus height, crypt depth, and muscle thickness (and inner (circular) and/or outer (longitudinal) muscular layer)) additionally increased. The rats immediately gained weight, ultimately to the weight of normal healthy rats. Ulcerative colitis. Controls exhibited pertinent ulceration, initial weight loss, and then decreased weight gain. BPC 157 rats immediately gained weight, ultimately to the weight of normal healthy rats, and had consistently less ulcerations. Ulcerative colitis+small bowel resection. Ulcerative colitis significantly aggravated all these parameters. BPC 157 retained the same beneficial effects, decreased ulcerative colitis, improved intestinal adaptation, villus height, crypt depth, and muscle thickness (and inner (circular) and/or outer (longitudinal) muscular layer)) additionally increased, early weight gain, ultimately to the weight of normal healthy rats. Conclusion. In addition to the recovery of the rats with short bowel syndrome or ulcerative colitis, BPC 157 can cure rats with short bowel syndrome complicated with ulcerative colitis.

BPC 157; short bowel syndrome; ulcerative colitis

nije evidentirano